Assembly Biosciences reported a net loss of $3.9 million, or $0.20 per share, for the quarter ended June 30, 2026, compared to a $10.2 million loss in the prior year period. Collaboration revenue with Gilead rose to $13.4 million from $9.6 million, driven by a $5.1 million cumulative catch-up adjustment. The company completed $115 million in gross financing and holds $320.4 million in cash and marketable securities as of June 30, 2026. Strategic updates include expanding ABI-6250 into cholestatic liver diseases with a Phase 2 study expected in Q1 2027, and Gilead selecting GS-1179 for a Phase 2 trial by year-end 2026. Assembly Biosciences is a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases.

Assembly Biosciences reported a net loss of $3.9 million ($0.20 per share) for the quarter ended June 30, 2026, compared to a $10.2 million loss in the prior year period. Collaboration revenue with Gilead rose to $13.4 million from $9.6 million, driven by a $5.1 million cumulative catch-up adjustment. The company completed $115 million in gross financing and holds $320.4 million in cash and marketable securities as of June 30, 2026. Strategic updates include expanding ABI-6250 into cholestatic liver diseases with a Phase 2 study expected in Q1 2027, and Gilead selecting GS-1179 to advance into a Phase 2 trial for recurrent genital herpes by year-end 2026. The company projects its cash runway extends into 2029, including a $75 million extension payment from Gilead due in Q4 2026. Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics for serious viral and liver diseases.